Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Long-Term Investments (2020 - 2021)

Tango Therapeutics has reported Long-Term Investments over the past 2 years, most recently at $166.8 million for Q2 2021.

  • Quarterly results put Long-Term Investments at $166.8 million for Q2 2021, changed N/A from a year ago — trailing twelve months through Jun 2021 was $166.8 million (changed N/A YoY), and the annual figure for FY2020 was $166.8 million, changed.
  • Long-Term Investments for Q2 2021 was $166.8 million at Tango Therapeutics, roughly flat from $166.8 million in the prior quarter.
  • Over the last five years, Long-Term Investments for TNGX hit a ceiling of $166.8 million in Q4 2020 and a floor of $166.8 million in Q3 2020.